AC Immune Corp (ACIU): רווח למניה בשנים עשר החודשים האחרונים

AC Immune relies on strategic partnerships with pharma giants to fund its testing. High profitability is sustained by a streamlined international cold chain for component supply. Net income per share over the last four quarters on this GURU.Markets platform chart shows that the indicator level is -0.52. The issuer's financial success is currently based entirely on grants and the results of clinical trials for Alzheimer's disease.

The efficiency of logistics chains for delivering molecules to clinics directly impacts the operating expenses of AC Immune (ACIU), which is reflected in the final net earnings per share. By analyzing the earnings per share slice over the last 12 months, an investor assesses the real business yield over a rolling period, where any sharp deviations in the curve signal a risk of overpaying for the asset.